Trial Profile
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Oregovomab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Nelfinavir; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Proof of concept; Therapeutic Use
- 05 Jun 2018 Status changed to discontinued due to the replacement of gemcitabine/ leucovorin/ Fluorouracil (GEM/LV/FU) by FOLFIRINOX and GEM/abraxane as standard of care for pancreatic adenocarcinoma as reported by results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2018 Results presented in an OncoQuest media release.